Product Reviews
Categories
- Alternative Medicine
- Cancer
- Acute Promyelocytic Leukemia
- Anal Cancer
- Bladder Cancer
- Breast cancer
- Colorectal cancer
- Endometrial Cancer
- Esophageal Cancer
- Gallbladder cancer
- Gastric Cancer
- Glioblastma
- Head and Neck Cancer
- Liver Cancer
- Lung Cancer
- Lymphoma
- Melanoma
- Nasopharyngeal Cancer
- Non-Hodgkin's Disease
- Ovarian Cancer
- Pancreatic Cancer
- Prostate cancer
- Renal Cancer
- Thyroid Cancer
- Cardiovascular disease
- Central Nervous System
- Constipation
- Diabetes
- Fatty Liver
- Irritable Bowel Syndrome
- Longevity
- Motherhood
- Obesity
- Others
- Psoriasis
- Respiratory Disease
- Rheumatoid Arthritis
Archives
Tag Archives: Survival
Yunzhi Slows Progression of Advanced Non-small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths, but most patients (over 69%) were diagnosed at advanced stages. Although polysaccharide peptides (PSP), isolated from the fungus Yunzhi (Coriolus versicolor), have been reported to have anti-tumor effects … Continue reading
Posted in Alternative Medicine, Cancer, Non Small Cell Lung Cancer
Tagged Coriolus versicolor, disease progression, IgG, IgM, Immune system, leukocyte, neutrophil, Non small cell lung cancer, NSCLC, Survival, Yunzhi
Comments Off on Yunzhi Slows Progression of Advanced Non-small Cell Lung Cancer
Bevacizumab Beneficial in Newly Diagnosed Glioblastoma?
A large study of patients with newly diagnosed glioblastoma multiforme suggests that the addition of bevacizumab (Avastin) and irinotecan (Camptosar) to standard chemoradiation can extend survival (progression and overall survival) by 6 months. Bevacizumab (Avastin) is an inhibitor of vascular … Continue reading
Posted in Cancer, Glioblastma
Tagged Avastin, bevacizumab, camptosar, chemoradiation, glioblastoma multiforme, Irinotecan, progression-free survival, Survival, Temodar, temozolomide
Comments Off on Bevacizumab Beneficial in Newly Diagnosed Glioblastoma?
First-Line Erlotinib Triples Progression-Free Survival in NSCLC in Chinese Population
First-line erlotinib (Tarceva) tripled the progression-free survival in advanced non–small cell lung carcinoma (NSCLC) patients who had endothelial growth factor receptor (EGFR)-activating mutation, according to the OPTIMAL study presented at the 35th European Society for Medical Oncology Congress. The study … Continue reading
Posted in Cancer, Lung Cancer, Non Small Cell Lung Cancer
Tagged carboplatin, endothelial growth factor receptor, erlotinib, gemcitabine, Gemzar, non–small cell lung carcinoma, NSCLC, OPTIMAL, progression-free, Survival, Tarceva
Comments Off on First-Line Erlotinib Triples Progression-Free Survival in NSCLC in Chinese Population
Cetuximab (Erbitux) Reduces Disease Progression in Triple Negative Breast Cancer
Patients with triple negative breast cancer usually have poor prognosis, but a new drug might soon be available to improve the survival in these patients. Mid-stage study results presented at the European Society for Medical Oncology congress indicated that cetuximab(Erbitux) … Continue reading
Posted in Breast cancer, Cancer
Tagged Cetuximab, Cisplatin, disease progression, Erbitux, Survival, triple negative breast cancer
Comments Off on Cetuximab (Erbitux) Reduces Disease Progression in Triple Negative Breast Cancer
Novel Agent Significantly Improves Survival in Men with Advanced Prostate Cancer
Great news for patients with advanced prostate cancer. A new investigational agent, abiraterone acetate, was shown to significantly improved survival in men with metastatic castration-resistant prostate cancer. Abiraterone acetate is an investigational agent being developed by Ortho Biotech. It acts … Continue reading
Posted in Cancer, Prostate cancer
Tagged abiraterone, androgen, castration-resistant, CYP17, docetaxel, Ortho Biotech, prednisone, Prostate cancer, Survival
Comments Off on Novel Agent Significantly Improves Survival in Men with Advanced Prostate Cancer
A New Treatment Option for patients with Gastric Cancer
Gastric cancer is the fourth most commonly diagnosed cancer and the second most common cause of cancer-related deaths worldwide. Previous study has found that patients with operable disease have a 5-year survival rate of 36%. In patients with advanced or … Continue reading
Posted in Cancer, Gastric Cancer
Tagged 5-Fluorouracil, capecitabine, chemotherapy, Cisplatin, Gastric Cancer, Gastro-esophageal Junction Cancer, Herceptin, Survival, Trastuzumab, Xeloda
Comments Off on A New Treatment Option for patients with Gastric Cancer
